Sex disparities in patients with symptomatic severe aortic stenosis - 26/05/21
Résumé |
Background |
We evaluated whether there is equitable distribution across sexes of treatment and outcomes for aortic valve replacement (AVR), via surgical (SAVR) or transcatheter (TAVR) methods, in symptomatic severe aortic stenosis (ssAS) patients.
Methods |
Using de-identified data, we identified 43,822 patients with ssAS (2008-2016). Multivariate competing risk models were used to determine the likelihood of any AVR, while accounting for the competing risk of death. Association between sex and 1-year mortality, stratified by AVR status, was evaluated using multivariate Cox regression models with AVR as a time-dependent variable.
Results |
Among patients with ssAS, 20,986 (47.9%) were female. Females were older (median age 81 vs. 78, P<0.001), more likely to have body mass index <20 (8.5% vs. 3.5%), and home oxygen use (4.4% vs. 3.4%, P<0001 for all). Overall, 12,129 (27.7%) patients underwent AVR for ssAS. Females were less likely to undergo AVR compared with males (24.1% vs. 31.0%, adjusted hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.77-0.83), but when treated, were more likely to undergo TAVR (37.9% vs. 30.9%, adjusted HR 1.21, 95% CI 1.15-1.27). Untreated females and males had similarly high rates of mortality at 1 year (31.1% vs. 31.3%, adjusted HR 0.98, 95% CI 0.94-1.03). Among those undergoing AVR, females had significantly higher mortality (10.2% vs. 9.4%, adjusted HR 1.24, 95% CI 1.10-1.41), driven by increased SAVR-associated mortality (9.0% vs. 7.6%, adjusted HR 1.43, 95% CI 1.21-1.69).
Conclusions |
Treatment rates for ssAS patients remain suboptimal with disparities in female treatment.
Le texte complet de cet article est disponible en PDF.Plan
| Funding: This study was funded by Edwards Lifesciences, which was not involved in the study design, analysis and interpretation of data, or the writing of the report. Dr Lowenstern reports funding through NIH T-32 training grant #5 T32 HL069749-14. |
Vol 237
P. 116-126 - juillet 2021 Retour au numéro
Article précédent
- Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry
- Iván J. Núñez-Gil, Iván Olier, Gisela Feltes, María C. Viana-Llamas, Charbel Maroun-Eid, Rodolfo Romero, Inmaculada Fernández-Rozas, Aitor Uribarri, Victor M. Becerra-Muñoz, Emilio Alfonso-Rodriguez, Marcos García-Aguado, Javier Elola, Alex Castro-Mejía, Martino Pepe, Juan Fortunato Garcia-Prieto, Adelina Gonzalez, Fabrizio Ugo, Enrico Cerrato, Elvira Bondia, Sergio Raposeiras-Roubin, Jorge L. Jativa Mendez, Carolina Espejo, Álvaro López-Masjuan, Francisco Marin, Javier López-Pais, Mohammad Abumayyaleh, Miguel Corbi-Pascual, Christoph Liebetrau, Harish Ramakrishna, Vicente Estrada, Carlos Macaya, Antonio Fernandez-Ortiz, HOPE COVID-19 Investigators (Cols Appendix)
- Venous thromboembolism among patients hospitalized with COVID-19 at Veterans Health Administration Hospitals
- J. Antonio Gutierrez, Marc D. Samsky, Ryan D. Schulteis, Lin Gu, Rajesh V. Swaminathan, Aaron W. Aday, Sunil V. Rao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?